S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Global shares mostly rise after House approves debt ceiling deal
Having Trouble in Your Trading? (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Global shares mostly rise after House approves debt ceiling deal
Having Trouble in Your Trading? (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Global shares mostly rise after House approves debt ceiling deal
Having Trouble in Your Trading? (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Global shares mostly rise after House approves debt ceiling deal
Having Trouble in Your Trading? (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
NASDAQ:TTNP

Titan Pharmaceuticals (TTNP) Stock Forecast, Price & News

$0.76
-0.01 (-1.29%)
(As of 05/31/2023 ET)
Compare
Today's Range
$0.72
▼
$0.78
50-Day Range
$0.73
▼
$0.83
52-Week Range
$0.36
▼
$1.59
Volume
12,625 shs
Average Volume
14,560 shs
Market Capitalization
$11.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

TTNP stock logo

About Titan Pharmaceuticals (NASDAQ:TTNP) Stock

Titan Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, proNeura. Its lead product is probuphine, a buprenorphine implant for the maintenance treatment of opioid addiction. The company was founded by Louis R. Bucalo on February 7, 1992 and is headquartered in South San Francisco, CA.

Receive TTNP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Titan Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

TTNP Stock News Headlines

June 1, 2023 | americanbankingnews.com
Titan Pharmaceuticals (NASDAQ:TTNP) Now Covered by Analysts at StockNews.com
May 26, 2023 | finance.yahoo.com
TTNP - Titan Pharmaceuticals, Inc.
June 1, 2023 | Legacy Research (Affiliate) (Ad)
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty
A unique type of investment could help you make more money than you will need for the rest of your life. It’s what we call the “Amazon secret royalty program.” It’s an income stream that allows you to collect $1,000s… $10,000s… or more every year! Learn how to collect your first payout before June 13th.
May 25, 2023 | americanbankingnews.com
Titan Pharmaceuticals (NASDAQ:TTNP) Coverage Initiated at StockNews.com
May 23, 2023 | sports.yahoo.com
Watch: Prowling tiger bows to ‘titan herd’ of elephants
May 17, 2023 | americanbankingnews.com
Titan Pharmaceuticals (NASDAQ:TTNP) Now Covered by StockNews.com
May 1, 2023 | americanbankingnews.com
StockNews.com Initiates Coverage on Titan Pharmaceuticals (NASDAQ:TTNP)
April 30, 2023 | americanbankingnews.com
Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Sees Large Increase in Short Interest
June 1, 2023 | Legacy Research (Affiliate) (Ad)
Sell Every Stock, Except ONE (Ticker Revealed)
We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.
April 22, 2023 | americanbankingnews.com
StockNews.com Begins Coverage on Titan Pharmaceuticals (NASDAQ:TTNP)
March 22, 2023 | seekingalpha.com
TTNP Titan Pharmaceuticals, Inc.
March 21, 2023 | americanbankingnews.com
Titan Pharmaceuticals (NASDAQ:TTNP) Coverage Initiated by Analysts at StockNews.com
December 15, 2022 | finance.yahoo.com
Titan Pharmaceuticals Provides Shareholder Update
December 12, 2022 | nz.finance.yahoo.com
Titan Pharmaceuticals Inc. Announces Licensing Agreement with Ocular Therapeutix Inc.
November 21, 2022 | bizjournals.com
Chapel Hill surgical tech company shapes plan to keep Nasdaq listing
November 17, 2022 | finance.yahoo.com
Titan Pharmaceuticals Third Quarter 2022 Earnings: US$0.18 loss per share (vs US$0.19 loss in 3Q 2021)
November 4, 2022 | msn.com
Titan, GAIL, TVS Motor, Britannia & Other Stocks to Release Q2 Results Today
August 17, 2022 | benzinga.com
Titan Pharmaceuticals Announces Board Expansion...
August 16, 2022 | finance.yahoo.com
Titan Pharmaceuticals Announces Board Expansion and Management Changes
July 11, 2022 | insidermonkey.com
Hedge Fund and Insider Trading News: George Soros, Jim Simons, Three Arrows Capital, Rocket Companies Inc (RKT), Titan Pharmaceuticals, Inc. (TTNP), and More
July 11, 2022 | finance.yahoo.com
Activist Investing Nominates Slate of Highly Qualified Director Candidates for Election to the Board of Directors of Titan Pharmaceuticals at Upcoming Special Meeting of Stockholders
July 9, 2022 | finance.yahoo.com
Here's Why We're Watching Titan Pharmaceuticals' (NASDAQ:TTNP) Cash Burn Situation
July 6, 2022 | benzinga.com
Titan Pharmaceuticals Gets FDA Clearance To Commence Opioid Disorder Study
July 5, 2022 | nasdaq.com
Titan Pharma Says FDA Clears IND Application For Nalmefene Implant
July 5, 2022 | finance.yahoo.com
Titan Pharmaceuticals Announces FDA Clearance of IND Application for Nalmefene Implant
June 10, 2022 | finance.yahoo.com
Activist Investing Discloses 9.9% Ownership Interest in Titan Pharmaceuticals, Inc.
April 25, 2022 | apnews.com
Activist Investing Announces 5.6% Ownership Interest in Titan Pharmaceuticals, Inc.
See More Headlines
Receive TTNP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Titan Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

TTNP Company Calendar

Last Earnings
3/30/2021
Today
6/01/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TTNP
CUSIP
N/A
CIK
910267
Web
www.titanpharm.com
Phone
(650) 244-4990
Fax
650-244-4956
Employees
11
Year Founded
1992

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-10,210,000.00
Net Margins
-2,017.49%
Pretax Margin
-2,017.49%
Return on Equity
-363.89%
Return on Assets
-179.45%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.73
Quick Ratio
0.69

Sales & Book Value

Annual Sales
$560,000.00
Price / Sales
20.49
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.02) per share
Price / Book
-38.20

Miscellaneous

Outstanding Shares
15,020,000
Free Float
10,827,000
Market Cap
$11.48 million
Optionable
Optionable
Beta
1.10

Social Links


Key Executives

  • David Elliot Lazar
    Chairman, Chief Executive & Financial Officer
  • Katherine L. Beebe-DeVarney
    President, Chief Operating Officer & Director
  • Brian E. Crowley
    Vice President-Finance

Key Competitors

View All Competitors

Insiders

View All Insider Transactions













TTNP Stock - Frequently Asked Questions

How have TTNP shares performed in 2023?

Titan Pharmaceuticals' stock was trading at $0.7831 at the start of the year. Since then, TTNP stock has decreased by 2.4% and is now trading at $0.7640.
View the best growth stocks for 2023 here.

Are investors shorting Titan Pharmaceuticals?

Titan Pharmaceuticals saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 46,200 shares, a decline of 26.1% from the April 30th total of 62,500 shares. Based on an average daily volume of 15,000 shares, the days-to-cover ratio is presently 3.1 days.
View Titan Pharmaceuticals' Short Interest.

How were Titan Pharmaceuticals' earnings last quarter?

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) issued its quarterly earnings results on Tuesday, March, 30th. The specialty pharmaceutical company reported ($0.86) earnings per share for the quarter, topping analysts' consensus estimates of ($1.33) by $0.47. Titan Pharmaceuticals had a negative net margin of 2,017.49% and a negative trailing twelve-month return on equity of 363.89%.

When did Titan Pharmaceuticals' stock split?

Shares of Titan Pharmaceuticals reverse split on Tuesday, December 1st 2020. The 1-30 reverse split was announced on Monday, November 30th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Monday, November 30th 2020. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Titan Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Titan Pharmaceuticals investors own include Bionano Genomics (BNGO), Gran Tierra Energy (GTE), Matinas BioPharma (MTNB), Organigram (OGI), Zosano Pharma (ZSAN), Novan (NOVN), ADMA Biologics (ADMA), Aeterna Zentaris (AEZS), CNBX Pharmaceuticals (CNBX) and Pennsylvania Real Estate Investment Trust (PEI).

What is Titan Pharmaceuticals' stock symbol?

Titan Pharmaceuticals trades on the NASDAQ under the ticker symbol "TTNP."

How do I buy shares of Titan Pharmaceuticals?

Shares of TTNP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Titan Pharmaceuticals' stock price today?

One share of TTNP stock can currently be purchased for approximately $0.76.

How much money does Titan Pharmaceuticals make?

Titan Pharmaceuticals (NASDAQ:TTNP) has a market capitalization of $11.48 million and generates $560,000.00 in revenue each year.

How can I contact Titan Pharmaceuticals?

Titan Pharmaceuticals' mailing address is 400 OYSTER POINT BLVD SUITE 505, SAN FRANCISCO CA, 94080. The official website for the company is www.titanpharm.com. The specialty pharmaceutical company can be reached via phone at (650) 244-4990, via email at skilmer@titanpharm.com, or via fax at 650-244-4956.

This page (NASDAQ:TTNP) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -